FR2527444B1 - Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite - Google Patents

Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite

Info

Publication number
FR2527444B1
FR2527444B1 FR8308586A FR8308586A FR2527444B1 FR 2527444 B1 FR2527444 B1 FR 2527444B1 FR 8308586 A FR8308586 A FR 8308586A FR 8308586 A FR8308586 A FR 8308586A FR 2527444 B1 FR2527444 B1 FR 2527444B1
Authority
FR
France
Prior art keywords
refined
toxicity
composition containing
therapeutic composition
endotoxin free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8308586A
Other languages
English (en)
French (fr)
Other versions
FR2527444A1 (fr
Inventor
Edgar Ernst Ribi
John Leonard Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FR2527444A1 publication Critical patent/FR2527444A1/fr
Application granted granted Critical
Publication of FR2527444B1 publication Critical patent/FR2527444B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR8308586A 1982-05-26 1983-05-25 Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite Expired FR2527444B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/382,406 US4435386A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product

Publications (2)

Publication Number Publication Date
FR2527444A1 FR2527444A1 (fr) 1983-12-02
FR2527444B1 true FR2527444B1 (fr) 1987-02-20

Family

ID=23508812

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8308586A Expired FR2527444B1 (fr) 1982-05-26 1983-05-25 Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite

Country Status (7)

Country Link
US (1) US4435386A (enExample)
JP (1) JPS58222027A (enExample)
CA (1) CA1225591A (enExample)
DE (1) DE3318568C2 (enExample)
FR (1) FR2527444B1 (enExample)
GB (1) GB2122084B (enExample)
IT (1) IT1164244B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505899A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
US4497730A (en) * 1984-04-03 1985-02-05 The United States Of America As Represented By The Department Of Health And Human Services Method for obtaining periplasmic proteins from bacterial cells using chloroform
NL8401226A (nl) * 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
US4629722A (en) * 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
WO1998035665A1 (fr) * 1997-02-14 1998-08-20 Ajinomoto Co., Inc. Antagonistes des endotoxines
WO2000058456A2 (en) 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP2283868B1 (en) 2002-07-15 2016-03-30 Board of Regents, The University of Texas System Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US20120244185A1 (en) 2009-09-16 2012-09-27 Vaxart ,Inc. Immunization strategy to prevent h1n1 infection
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
HK1225631A1 (zh) 2013-09-19 2017-09-15 Novavax, Inc. 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
EA033248B1 (ru) 2014-02-20 2019-09-30 Вэксарт, Инк. Композиция и способ индукции иммунного ответа
JP6912394B2 (ja) 2015-06-12 2021-08-04 バクサート インコーポレイテッド Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
AU2017294751B2 (en) 2016-07-13 2023-10-05 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2

Also Published As

Publication number Publication date
JPS6234730B2 (enExample) 1987-07-28
DE3318568C2 (de) 1987-01-15
DE3318568A1 (de) 1984-01-12
IT1164244B (it) 1987-04-08
US4435386A (en) 1984-03-06
JPS58222027A (ja) 1983-12-23
GB2122084A (en) 1984-01-11
FR2527444A1 (fr) 1983-12-02
CA1225591A (en) 1987-08-18
GB2122084B (en) 1986-02-05
GB8313054D0 (en) 1983-06-15
IT8321289A0 (it) 1983-05-25

Similar Documents

Publication Publication Date Title
FR2527444B1 (fr) Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite
FR2527443B1 (fr) Composition contenant de l'endotoxine raffinee et medicament la contenant
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
NO931843L (no) Legemiddelavgivende porfyrinpreparater og fremgangsmaater
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
IT8027029A0 (it) Complessi platino-diamminici e formulazioni farmaceutiche per il trattamento del cancro che licontengono.
IT1099928B (it) Apparecchiatura per il trattamento di parti del corpo
ZA858676B (en) Method and system for removing immunosppressive components from the blood of mammals
ES8203599A1 (es) Un aparato terapeutico para uso en crioterapia
SE8001685L (sv) Karcinostatiskt och immunostimulerande medel innehallande lysofosfolipid och fosfolipid och forfarande for framstellning derav
PT76325B (en) Process for the preparation of polysaccharide-protein complexes from bacterial capsules
GB2276623A (en) Cytotoxic drug therapy
FR2406641A1 (fr) 2,6-diaminonebularines et leur application therapeutique
SE8404707D0 (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ES444494A1 (es) Procedimiento para la preparacion de antracicliononas opti- camente activas.
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
SE8302519D0 (sv) Solfilterkompositioner
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
ES2086651T3 (es) Nuevos compuestos, denominados "leustroducsinas", su preparacion y sus utilizaciones terapeuticas.
FR2423223A1 (fr) Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique
IT8121484A0 (it) Estratto da piante del genere epimedium, procedimento per lapreparazione di detto estratto, agente immunostimolante che comprende detto estratto come componente efficace e immunoterapia mediante l'impiego di detto estratto.
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
EP0301449A3 (en) Enantiomers of propafenone-containing therapeutic agents
SE8201308D0 (sv) Alkylendiaminderivat och forfarande for framstellning derav

Legal Events

Date Code Title Description
ER Errata listed in the french official journal (bopi)

Free format text: 48/83

ST Notification of lapse